Eyevensys announced appointment of Dr Violaine Desort-Henin as Clinical Director

Eyevensys, an innovative ophthalmic therapy company, announced the appointment Dr. Violaine Desort-Hénin as Clinical Director. In this position, Dr. Desort-Hénin will be responsible for overseeing the development of Eyevensys clinical development program.

Dr. Violaine Desort-Hénin commented:
“Joining such an innovative company at this stage is an amazing challenge which I am thrilled to face alongside the team. Eyevensys innovative technology will push the present limits of ocular treatments and revolutionize patient’s lives. It is a genuinely exciting moment in any company’s life when workbench developments are translated into clinics, and I am proud to be on board!”

Dr. Violaine Desort-Hénin combines several competences, from vet medicine and surgery to toxicology and clinical trial management, particularly in the area of ophthalmology. Various professional experiences have enabled her to acquire a translational medical expertise and a deep understanding of the complex physiopathology underlying ocular diseases. She was previously Head of Preclinical and Clinical Development in a listed biotech company for over 5 years. During her previous tenure, she participated in all phases of development up to clinical Phase III and participated in the design of strategic international programs.

“We welcome Violaine Desort-Hénin to our senior management team. Dr. Desort-Henin brings solid and innovative clinical and regulatory expertise as well as a successful track record that will help accelerate the development of our lead program in Uveitis at a crucial juncture for the Company,” said Eyevensys’ CEO, Raffy Kazandjian.